Literature DB >> 29991502

Remission of Spontaneous Canine Tumors after Systemic Cellular Viroimmunotherapy.

Teresa Cejalvo1, Ana Judith Perisé-Barrios1, Isabel Del Portillo2, Eduardo Laborda3, Miguel A Rodriguez-Milla1, Isabel Cubillo1, Fernando Vázquez2, David Sardón2, Manuel Ramirez4, Ramon Alemany3, Noemí Del Castillo2, Javier García-Castro5.   

Abstract

Dogs with spontaneous tumors treated in veterinary hospitals offer an excellent opportunity for studying immunotherapies, including oncolytic viruses. Oncolytic viruses have advanced into the clinic as an intratumorally administered therapeutic; however, intravenous delivery has been hindered by neutralization in the blood. To circumvent this hurdle, mesenchymal stem cells have been used as a "Trojan horse." Here, we present the treatment of 27 canine patients with cancer with canine mesenchymal stem cells infected with ICOCAV17, a canine oncolytic adenovirus. No significant adverse effects were found. The response rate was 74%, with 14.8% showing complete responses, including total remissions of lung metastasis. We detected virus infection, stromal degeneration, and immune cell infiltration in tumor biopsies after 4 weeks of treatment. The increased presence of antiadenoviral antibodies in the peripheral blood of treated dogs did not appear to prevent the clinical benefit of this therapy. These data indicate that oncolytic viruses loaded in mesenchymal stem cells represent an effective cancer immunotherapy.Significance: The classical clinical limitations of antitumoral viroimmunotherapy can be overcome by use of mesenchymal stem cells.Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/78/17/4891/F1.large.jpg Cancer Res; 78(17); 4891-901. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2018        PMID: 29991502     DOI: 10.1158/0008-5472.CAN-17-3754

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  First-in-Human, First-in-Child Trial of Autologous MSCs Carrying the Oncolytic Virus Icovir-5 in Patients with Advanced Tumors.

Authors:  David Ruano; José A López-Martín; Lucas Moreno; Álvaro Lassaletta; Francisco Bautista; Maitane Andión; Carmen Hernández; África González-Murillo; Gustavo Melen; Ramón Alemany; Luis Madero; Javier García-Castro; Manuel Ramírez
Journal:  Mol Ther       Date:  2020-01-21       Impact factor: 11.454

2.  Genetic and Immune Changes Associated with Disease Progression under the Pressure of Oncolytic Therapy in A Neuroblastoma Outlier Patient.

Authors:  Lidia Franco-Luzón; Sandra García-Mulero; Rebeca Sanz-Pamplona; Gustavo Melen; David Ruano; Álvaro Lassaletta; Luís Madero; África González-Murillo; Manuel Ramírez
Journal:  Cancers (Basel)       Date:  2020-04-28       Impact factor: 6.639

3.  Canine Adipose-Derived Mesenchymal Stem Cells (cAdMSCs) as a "Trojan Horse" in Vaccinia Virus Mediated Oncolytic Therapy against Canine Soft Tissue Sarcomas.

Authors:  Ivan Petrov; Ivaylo Gentschev; Anna Vyalkova; Mohamed I Elashry; Michele C Klymiuk; Stefan Arnhold; Aladar A Szalay
Journal:  Viruses       Date:  2020-07-12       Impact factor: 5.048

Review 4.  Translational Animal Models Provide Insight Into Mesenchymal Stromal Cell (MSC) Secretome Therapy.

Authors:  Rebecca M Harman; Charlotte Marx; Gerlinde R Van de Walle
Journal:  Front Cell Dev Biol       Date:  2021-03-19

5.  Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma.

Authors:  Alvaro Morales-Molina; Stefano Gambera; Angela Leo; Javier García-Castro
Journal:  J Immunother Cancer       Date:  2021-03       Impact factor: 13.751

6.  Identification and Validation of Immune-Related Gene for Predicting Prognosis and Therapeutic Response in Ovarian Cancer.

Authors:  Zhao-Cong Zhang; Jun-Nan Guo; Ning Zhang; Zhi-Qiang Wang; Ge Lou; Bin-Bin Cui; Chang Yang
Journal:  Front Immunol       Date:  2021-11-22       Impact factor: 7.561

7.  Safety and Efficacy of an Oncolytic Adenovirus as an Immunotherapy for Canine Cancer Patients.

Authors:  Clara Martín-Carrasco; Pablo Delgado-Bonet; Beatriz Davinia Tomeo-Martín; Josep Pastor; Claudia de la Riva; Paula Palau-Concejo; Noemí Del Castillo; Javier García-Castro; Ana Judith Perisé-Barrios
Journal:  Vet Sci       Date:  2022-06-28

8.  Safety studies and viral shedding of intramuscular administration of oncolytic vaccinia virus TG6002 in healthy beagle dogs.

Authors:  Jérémy Béguin; Virginie Nourtier; Murielle Gantzer; Sandrine Cochin; Johann Foloppe; Jean-Marc Balloul; Eve Laloy; Dominique Tierny; Bernard Klonjkowski; Eric Quemeneur; Christelle Maurey; Philippe Erbs
Journal:  BMC Vet Res       Date:  2020-08-25       Impact factor: 2.741

Review 9.  Oncolytic Viruses for Canine Cancer Treatment.

Authors:  Diana Sánchez; Gabriela Cesarman-Maus; Alfredo Amador-Molina; Marcela Lizano
Journal:  Cancers (Basel)       Date:  2018-10-27       Impact factor: 6.639

10.  Combination Therapy with Reovirus and ATM Inhibitor Enhances Cell Death and Virus Replication in Canine Melanoma.

Authors:  Masaya Igase; Shusaku Shibutani; Yosuke Kurogouchi; Noriyuki Fujiki; Chung Chew Hwang; Matt Coffey; Shunsuke Noguchi; Yuki Nemoto; Takuya Mizuno
Journal:  Mol Ther Oncolytics       Date:  2019-08-28       Impact factor: 7.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.